Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2000 Jan 18;82(3):524–528. doi: 10.1054/bjoc.1999.0957

Idarubicinol myelotoxicity: a comparison of in vitro data with clinical outcome in patients treated with high-dose idarubicin

C Corsini 1, M Ghielmini 2, P Mancuso 1, F Tealdo 1, M Paolucci 1, M Zucchetti 3, P F Ferrucci 1, E Cocorocchio 1, M Mezzetti 4, A Mori 5, M Riggi 5, M D'Incalci 3, G Martinelli 1
PMCID: PMC2363340  PMID: 10682659

Abstract

We evaluated in vitro the toxicity of idarubicin and its active metabolite idarubicinol on haematopoietic progenitors, using human umbilical cord blood and peripheral blood progenitors to obtain dose–response curves. We treated 16 patients with poor prognosis lymphoma in a phase I–II trial of high-dose idarubicin and melphalan and investigated if idarubicinol persisting in patients' plasma at the time of transplantation (day 0), on day +1 and +2 could result in an inhibition of infused progenitors. Colony inhibition was correlated with pharmacokinetic data and with the time of patients' engraftment. Plasma samples obtained before idarubicin treatment demonstrated a colony-stimulating effect, increasing the cloning efficiency by 72%. The inhibitory activity on colony forming unit granulocyte–macrophage (CFU-GM) of patients' plasma collected on the day of transplantation was lower than expected from dose–response curves (21% measured vs 70% expected). The time to patients' WBC and PLT recovery correlated with the amount of CD34+ cells reinfused and, to a lesser extent, with the colony-inhibiting effect of patients' plasma. The correlation between idarubicinol concentration and CFU-GM inhibition was not significant. These data suggest that plasma drug concentration on the day of stem cell reinfusion may overestimate the toxicity of residual anthracyclines to the transplanted cells. © 2000 Cancer Research Campaign

Keywords: high-dose chemotherapy, idarubicin, idarubicinol, CFU-GM growth inhibition, haematotoxicity

Full Text

The Full Text of this article is available as a PDF (70.7 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Broggini M., Italia C., Colombo T., Marmonti L., Donelli M. G. Activity and distribution of iv and oral 4-demethoxydaunorubicin in murine experimental tumors. Cancer Treat Rep. 1984 May;68(5):739–747. [PubMed] [Google Scholar]
  2. Camaggi C. M., Strocchi E., Carisi P., Martoni A., Tononi A., Guaraldi M., Strolin-Benedetti M., Efthymiopoulos C., Pannuti F. Idarubicin metabolism and pharmacokinetics after intravenous and oral administration in cancer patients: a crossover study. Cancer Chemother Pharmacol. 1992;30(4):307–316. doi: 10.1007/BF00686301. [DOI] [PubMed] [Google Scholar]
  3. Campbell A. D., Wicha M. S. Extracellular matrix and the hematopoietic microenvironment. J Lab Clin Med. 1988 Aug;112(2):140–146. [PubMed] [Google Scholar]
  4. Case D. C., Jr, Gerber M. C., Gams R. A., Crawford J., Votaw M. L., Higano C. S., Pruitt B. T., Gould J. Phase II study of intravenous idarubicin in unfavorable non-Hodgkin's lymphoma. Leuk Lymphoma. 1993;10 (Suppl):73–79. doi: 10.3109/10428199309149116. [DOI] [PubMed] [Google Scholar]
  5. Chisesi T., Capnist G., de Dominicis E., Dini E. A phase II study of idarubicin (4-demethoxydaunorubicin) in advanced myeloma. Eur J Cancer Clin Oncol. 1988 Apr;24(4):681–684. doi: 10.1016/0277-5379(88)90299-4. [DOI] [PubMed] [Google Scholar]
  6. Dodion P., Sanders C., Rombaut W., Mattelaer M. A., Rozencweig M., Stryckmans P., Kenis Y. Effect of daunorubicin, carminomycin, idarubicin and 4-demethoxydaunorubicinol against human normal myeloid stem cells and human malignant cells in vitro. Eur J Cancer Clin Oncol. 1987 Dec;23(12):1909–1914. doi: 10.1016/0277-5379(87)90058-7. [DOI] [PubMed] [Google Scholar]
  7. Garay G., Dupont J., Dragosky M., Nucifora E., Cacchione R., Schnidrig P., Fernández J., Abel-Alzueta, Riveros D., Noviello V. Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma. Leuk Lymphoma. 1997 Aug;26(5-6):595–602. doi: 10.3109/10428199709050895. [DOI] [PubMed] [Google Scholar]
  8. Ghielmini M., Bosshard G., Capolongo L., Geroni M. C., Pesenti E., Torri V., D'Incalci M., Cavalli F., Sessa C. Estimation of the haematological toxicity of minor groove alkylators using tests on human cord blood cells. Br J Cancer. 1997;75(6):878–883. doi: 10.1038/bjc.1997.155. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Ghielmini M., Colli E., Bosshard G., Pennella G., Geroni C., Torri V., D'Incalci M., Cavalli F., Sessa C. Hematotoxicity on human bone marrow- and umbilical cord blood-derived progenitor cells and in vitro therapeutic index of methoxymorpholinyldoxorubicin and its metabolites. Cancer Chemother Pharmacol. 1998;42(3):235–240. doi: 10.1007/s002800050810. [DOI] [PubMed] [Google Scholar]
  10. Gianni A. M., Siena S., Bregni M., Lombardi F., Gandola L., Di Nicola M., Magni M., Peccatori F., Valagussa P., Bonadonna G. High-dose sequential chemo-radiotherapy with peripheral blood progenitor cell support for relapsed or refractory Hodgkin's disease--a 6-year update. Ann Oncol. 1993 Dec;4(10):889–891. doi: 10.1093/oxfordjournals.annonc.a058399. [DOI] [PubMed] [Google Scholar]
  11. Greenberg B. R., Reynolds R. D., Charron C. B., Squillace K. M., Lessin L. S., Case D. C., Jr, Gams R. A. Treatment of myelodysplastic syndromes with daily oral idarubicin. A phase I-II study. Cancer. 1993 Mar 15;71(6):1989–1992. doi: 10.1002/1097-0142(19930315)71:6<1989::aid-cncr2820710611>3.0.co;2-t. [DOI] [PubMed] [Google Scholar]
  12. Kuffel M. J., Reid J. M., Ames M. M. Anthracyclines and their C-13 alcohol metabolites: growth inhibition and DNA damage following incubation with human tumor cells in culture. Cancer Chemother Pharmacol. 1992;30(1):51–57. doi: 10.1007/BF00686485. [DOI] [PubMed] [Google Scholar]
  13. Liu L. F., Rowe T. C., Yang L., Tewey K. M., Chen G. L. Cleavage of DNA by mammalian DNA topoisomerase II. J Biol Chem. 1983 Dec 25;258(24):15365–15370. [PubMed] [Google Scholar]
  14. Léglise M. C., Darodes de Tailly P., Vignot J. L., Le Bot M. A., Le Roux A. M., Riché C. A cellular model for drug interactions on hematopoiesis: the use of human umbilical cord blood progenitors as a model for the study of drug-related myelosuppression of normal hematopoiesis. Cell Biol Toxicol. 1996 Feb;12(1):39–53. doi: 10.1007/BF00143393. [DOI] [PubMed] [Google Scholar]
  15. Minderman H., Linssen P., van der Lely N., Wessels J., Boezeman J., de Witte T., Haanen C. Toxicity of idarubicin and doxorubicin towards normal and leukemic human bone marrow progenitors in relation to their proliferative state. Leukemia. 1994 Mar;8(3):382–387. [PubMed] [Google Scholar]
  16. Muus P., Donnelly P., Schattenberg A., Linssen P., Minderman H., Dompeling E., de Witte T. Idarubicin-related side effects in recipients of T-cell-depleted allogeneic bone marrow transplants are schedule dependent. Semin Oncol. 1993 Dec;20(6 Suppl 8):47–52. [PubMed] [Google Scholar]
  17. Parchment R. E., Gordon M., Grieshaber C. K., Sessa C., Volpe D., Ghielmini M. Predicting hematological toxicity (myelosuppression) of cytotoxic drug therapy from in vitro tests. Ann Oncol. 1998 Apr;9(4):357–364. doi: 10.1023/a:1008245906772. [DOI] [PubMed] [Google Scholar]
  18. Robert J. Clinical pharmacokinetics of idarubicin. Clin Pharmacokinet. 1993 Apr;24(4):275–288. doi: 10.2165/00003088-199324040-00002. [DOI] [PubMed] [Google Scholar]
  19. Salmon S. E., Liu R. M., Casazza A. M. Evaluation of new anthracycline analogs with the human tumor stem cell assay. Cancer Chemother Pharmacol. 1981;6(2):103–109. doi: 10.1007/BF00262325. [DOI] [PubMed] [Google Scholar]
  20. Schott B., Robert J. Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells. Biochem Pharmacol. 1989 Jan 1;38(1):167–172. doi: 10.1016/0006-2952(89)90164-0. [DOI] [PubMed] [Google Scholar]
  21. Van der Lely N., De Witte T., Raemaekers J., Schattenberg A., Haanen C. Anthracyclines added to the conditioning regimen for allogeneic bone marrow transplantation are associated with a slower haematopoietic recovery. Bone Marrow Transplant. 1989 Mar;4(2):163–166. [PubMed] [Google Scholar]
  22. Vogler W. R., Velez-Garcia E., Weiner R. S., Flaum M. A., Bartolucci A. A., Omura G. A., Gerber M. C., Banks P. L. A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study. J Clin Oncol. 1992 Jul;10(7):1103–1111. doi: 10.1200/JCO.1992.10.7.1103. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES